Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temanogrel - Pfizer

Next Previous
X
Search
Drug Profile

Temanogrel - Pfizer

Alternative Names: APD-791; Temanogrel hydrochloride

Latest Information Update: 20 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Ildong Pharmaceutical; Pfizer
  • Class Anti-ischaemics; Antithrombotics; Benzamides; Cardiovascular therapies; Morpholines; Phenyl ethers; Pyrazoles; Small molecules; Vascular disorder therapies
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial ischaemia; Raynaud's disease
  • Suspended Arterial thrombosis
  • Discontinued Acute coronary syndromes

Most Recent Events

  • 20 Sep 2022 Arena Pharmaceuticals terminates phase II trial in Raynaud's disease (In adults, In the elderly) in the UK and USA (PO) due to a business decision (NCT04915950)
  • 23 Aug 2022 Arena Pharmaceuticals terminates a Phase-II clinical trial in Myocardial ischaemia (In the elderly, In adults) in Australia, Netherlands, USA, United Kingdom and Sweden(IV), due to business decision (EudraCT2020-000238-16)
  • 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top